Aslan Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary

Reuters04-12

* Aslan Pharmaceuticals Ltd reported a quarterly adjusted loss of 78 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.04. The lone analyst forecast for the quarter was for a loss of 65 cents per share.

* Reported revenue was zero; analysts expected zero.

* Aslan Pharmaceuticals Ltd's reported EPS for the quarter was a loss of 78 cents.

* The company reported a quarterly loss of $13.51 million.

* Aslan Pharmaceuticals Ltd shares had fallen by 12.2% this quarter and gained 3.4% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* Wall Street's median 12-month price target for Aslan Pharmaceuticals Ltd is $9.50

This summary was machine generated from LSEG data April 12 at 12:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Dec. 31 2023 -0.65 -0.78 Missed

Sep. 30 2023 -0.78 -0.56 Beat

Jun. 30 2023 -0.80 -0.11 Beat

Mar. 31 2023 -4.05 -1.29 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426896107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-12 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426896107","market":"sg","top_or_hot":-1,"title":"Aslan Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary","media":"Reuters","content":"<html><body><p>* Aslan Pharmaceuticals Ltd    reported a quarterly adjusted loss of 78 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.04.  The lone analyst forecast for the quarter was for a loss of 65 cents per share. </p><p>   * Reported revenue was zero; analysts expected zero. </p><p>   * Aslan Pharmaceuticals Ltd's reported EPS for the quarter was a loss of 78 cents.</p><p>   * The company reported a quarterly loss of $13.51 million.</p><p>   * Aslan Pharmaceuticals Ltd shares had fallen by 12.2% this quarter and gained 3.4% so far this year.</p><p>FORECAST CHANGES</p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" </p><p>   * Wall Street's median 12-month price target for Aslan Pharmaceuticals Ltd is $9.50 </p><p>This summary was machine generated from LSEG data April 12 at 12:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Dec. 31 2023      -0.65          -0.78          Missed</p><p>Sep. 30 2023      -0.78          -0.56          Beat</p><p>Jun. 30 2023      -0.80          -0.11          Beat</p><p>Mar. 31 2023      -4.05          -1.29          Beat</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aslan Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAslan Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-12 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Aslan Pharmaceuticals Ltd    reported a quarterly adjusted loss of 78 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASLN","symbol_name":"ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426896107","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426896107","pubTimestamp":1712924405,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Aslan Pharmaceuticals Ltd    reported a quarterly adjusted loss of 78 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ASLN":"ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)"},"translate_title":"阿斯兰制药有限公司报告截至12月的季度业绩——收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASLN":0.9},"content_text":"* Aslan Pharmaceuticals Ltd    reported a quarterly adjusted loss of 78 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.04.  The lone analyst forecast for the quarter was for a loss of 65 cents per share.    * Reported revenue was zero; analysts expected zero.    * Aslan Pharmaceuticals Ltd's reported EPS for the quarter was a loss of 78 cents.   * The company reported a quarterly loss of $13.51 million.   * Aslan Pharmaceuticals Ltd shares had fallen by 12.2% this quarter and gained 3.4% so far this year.FORECAST CHANGES   * The mean earnings estimate of analysts was unchanged in the last three months.    * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"    * Wall Street's median 12-month price target for Aslan Pharmaceuticals Ltd is $9.50 This summary was machine generated from LSEG data April 12 at 12:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDDec. 31 2023      -0.65          -0.78          MissedSep. 30 2023      -0.78          -0.56          BeatJun. 30 2023      -0.80          -0.11          BeatMar. 31 2023      -4.05          -1.29          Beat","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426896107"}